Natus Medical Inc (BABY) Receives Average Rating of “Hold” from Analysts

Natus Medical Inc (NASDAQ:BABY) has been given a consensus rating of “Hold” by the six research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $44.00.

BABY has been the subject of a number of research analyst reports. BidaskClub raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, March 17th. Zacks Investment Research raised shares of Natus Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 10th. Finally, ValuEngine lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a research note on Thursday, May 3rd.

Shares of Natus Medical traded up $0.40, hitting $35.95, on Monday, MarketBeat reports. The stock had a trading volume of 221,791 shares, compared to its average volume of 229,633. Natus Medical has a twelve month low of $28.00 and a twelve month high of $43.60. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of 24.79 and a beta of 0.48. The company has a quick ratio of 2.28, a current ratio of 3.06 and a debt-to-equity ratio of 0.31.

Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, April 25th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.24. Natus Medical had a negative net margin of 4.71% and a positive return on equity of 10.96%. The company had revenue of $128.60 million during the quarter, compared to analyst estimates of $125.91 million. During the same quarter in the previous year, the business earned $0.30 EPS. The firm’s revenue was up 3.1% on a year-over-year basis. research analysts expect that Natus Medical will post 1.62 earnings per share for the current year.

In other Natus Medical news, VP Dong Chune Christopher Chung sold 15,358 shares of the business’s stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $33.32, for a total transaction of $511,728.56. Following the sale, the vice president now directly owns 151,731 shares of the company’s stock, valued at approximately $5,055,676.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider James B. Hawkins sold 160,000 shares of the business’s stock in a transaction dated Monday, April 30th. The stock was sold at an average price of $33.47, for a total transaction of $5,355,200.00. Following the sale, the insider now directly owns 686,757 shares in the company, valued at $22,985,756.79. The disclosure for this sale can be found here. Insiders have sold a total of 183,358 shares of company stock worth $6,154,209 over the last three months. Insiders own 5.50% of the company’s stock.

Several hedge funds have recently modified their holdings of BABY. Voce Capital Management LLC bought a new stake in shares of Natus Medical in the 1st quarter valued at about $22,236,000. Nuveen Asset Management LLC raised its holdings in shares of Natus Medical by 1,599.6% in the 1st quarter. Nuveen Asset Management LLC now owns 498,854 shares of the medical equipment provider’s stock valued at $16,786,000 after purchasing an additional 469,502 shares during the period. BlackRock Inc. raised its holdings in shares of Natus Medical by 7.3% in the 1st quarter. BlackRock Inc. now owns 4,326,763 shares of the medical equipment provider’s stock valued at $145,597,000 after purchasing an additional 294,082 shares during the period. Millennium Management LLC bought a new stake in shares of Natus Medical in the 4th quarter valued at about $10,445,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Natus Medical in the 4th quarter valued at about $6,733,000. 89.20% of the stock is currently owned by institutional investors.

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply